Ironwood Pharmaceuticals Company Profile (NASDAQ:IRWD)

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals logoIronwood Pharmaceuticals, Inc. is a biotechnology company. The Company's products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. It operates through human therapeutics segment. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. It is engaged in developing therapeutic platforms for the treatment of vascular and fibrotic diseases, and refractory gastroesophageal reflux disease (GERD). Its IW-9179 is used for the treatment of gastroparesis and functional dyspepsia. The Company has conducted an exploratory Phase IIa clinical study of IW-3718 in patients with refractory GERD. It has two sGC development candidates, which include IW-1973 and IW-1701.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IRWD
  • CUSIP: 46333X10
Key Metrics:
  • Previous Close: $17.14
  • 50 Day Moving Average: $15.48
  • 200 Day Moving Average: $14.89
  • 52-Week Range: $8.18 - $17.31
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -39.81
  • P/E Growth: -0.61
  • Market Cap: $2.51B
  • Outstanding Shares: 146,223,000
  • Beta: 1.34
  • Net Margins: -34.29%
  • Return on Equity: -94.17%
  • Return on Assets: -11.60%
  • Debt-to-Equity Ratio: 6.10%
  • Current Ratio: 4.02%
  • Quick Ratio: 4.02%
Additional Links:
Companies Related to Ironwood Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (?)
Ratings Breakdown: 6 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $16.10 (5.96% downside)

Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateFirmActionRatingPrice TargetDetails
2/17/2017WedbushReiterated RatingNeutral$13.00View Rating Details
2/16/2017MizuhoReiterated RatingBuy$21.00View Rating Details
2/2/2017J P Morgan Chase & CoSet Price TargetBuy$21.00View Rating Details
1/30/2017Cowen and CompanyReiterated RatingOutperform$16.00View Rating Details
9/27/2016WallachBeth CapitalBoost Price TargetHold$15.00 -> $17.00View Rating Details
9/23/2016BTIG ResearchReiterated RatingBuy$15.00 -> $18.00View Rating Details
8/8/2016Leerink SwannReiterated RatingMarket Perform$10.00 -> $14.00View Rating Details
8/5/2016Barclays PLCBoost Price TargetEqual Weight$11.00 -> $12.00View Rating Details
4/28/2016JP Morgan CazenoveReiterated RatingOverweight$15.00View Rating Details
4/26/2016Morgan StanleyReiterated RatingHoldView Rating Details
3/23/2016Wood & CompanyInitiated CoveragePositiveView Rating Details
3/21/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$14.00View Rating Details
5/1/2015Cantor FitzgeraldReiterated RatingHold$13.50View Rating Details
4/27/2015Bank of America CorpInitiated CoverageBuy$19.00View Rating Details
(Data available from 2/22/2015 forward)


Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017Q416($0.24)($0.12)$77.34 million$87.50 millionViewN/AView Earnings Details
11/3/2016Q316($0.23)($0.18)$60.01 million$66.00 millionViewN/AView Earnings Details
8/4/2016Q216($0.15)($0.16)$54.49 million$54.40 millionViewN/AView Earnings Details
5/9/2016Q116($0.14)($0.08)$52.97 million$66.00 millionViewN/AView Earnings Details
2/18/2016Q415($0.17)($0.10)$44.78 million$53.30 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.25)$39.81 million$39.60 millionViewListenView Earnings Details
8/5/2015Q215($0.22)($0.34)$36.08 million$27.74 millionViewN/AView Earnings Details
5/5/2015Q115($0.23)($0.24)$32.30 million$28.90 millionViewN/AView Earnings Details
2/12/2015Q414($0.21)($0.27)$35.20 million$38.10 millionViewListenView Earnings Details
11/4/2014Q314($0.32)($0.30)$21.20 million$16.90 millionViewListenView Earnings Details
8/4/2014Q214($0.36)($0.38)$15.75 million$6.84 millionViewListenView Earnings Details
4/29/2014Q1($0.44)($0.38)$8.52 million$14.60 millionViewListenView Earnings Details
1/21/2014Q413($0.50)($0.43)$7.13 million$5.00 millionViewListenView Earnings Details
10/22/2013Q313($0.57)($0.51)$6.54 million$4.90 millionViewN/AView Earnings Details
7/23/2013Q2 2013($0.70)($0.57)$6.32 million$9.70 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.71)($0.87)$8.94 million$3.30 millionViewN/AView Earnings Details
1/15/2013Q4 2012($0.49)($0.41)$16.17 million$27.00 millionViewN/AView Earnings Details
10/16/2012$0.17$0.42ViewN/AView Earnings Details
7/17/2012($0.31)($0.38)ViewN/AView Earnings Details
5/1/2012($0.23)($0.34)ViewN/AView Earnings Details
2/28/2012($0.11)($0.07)ViewN/AView Earnings Details
11/7/2011($0.20)($0.21)ViewN/AView Earnings Details
8/11/2011($0.18)($0.19)ViewN/AView Earnings Details
5/12/2011($0.17)($0.19)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Current Year EPS Consensus Estimate: $-0.72 EPS
Next Year EPS Consensus Estimate: $-0.43 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.16)($0.08)($0.11)
Q2 20162($0.13)($0.12)($0.13)
Q3 20162($0.23)($0.22)($0.23)
Q4 20162($0.23)($0.21)($0.22)
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.03)($0.03)($0.03)
Q3 20171$0.00$0.00$0.00
Q4 20171$0.08$0.08$0.08
(Data provided by Zacks Investment Research)


Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Insider Ownership Percentage: 7.17%
Institutional Ownership Percentage: 96.01%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/14/2017Halley E GilbertInsiderSell37,385$16.75$626,198.75View SEC Filing  
1/12/2017Peter M HechtCEOSell65,987$15.67$1,034,016.29View SEC Filing  
12/5/2016Lawrence S OlanoffDirectorSell3,200$15.68$50,176.00View SEC Filing  
9/6/2016Lawrence S OlanoffDirectorSell3,200$13.72$43,904.00View SEC Filing  
8/19/2016Gina ConsylmanInsiderSell207$13.54$2,802.78View SEC Filing  
6/3/2016Lawrence S OlanoffDirectorSell2,200$12.92$28,424.00View SEC Filing  
5/25/2016Halley E GilbertInsiderSell20,275$12.19$247,152.25View SEC Filing  
3/11/2016Peter M HechtCEOSell120,000$10.72$1,286,400.00View SEC Filing  
3/7/2016Lawrence S OlanoffDirectorSell2,200$11.11$24,442.00View SEC Filing  
2/24/2016Edward P OwensDirectorBuy10,000$8.32$83,200.00View SEC Filing  
2/24/2016Gina ConsylmanCAOSell420$8.50$3,570.00View SEC Filing  
2/24/2016Mark G CurrieInsiderSell152,154$8.53$1,297,873.62View SEC Filing  
2/24/2016Thomas GraneyCFOSell563$8.50$4,785.50View SEC Filing  
12/15/2015Peter M. HechtCEOSell73,418$11.07$812,737.26View SEC Filing  
12/7/2015Lawrence S OlanoffDirectorSell2,200$11.77$25,894.00View SEC Filing  
9/4/2015Lawrence S OlanoffDirectorSell3,725$10.97$40,863.25View SEC Filing  
3/17/2015Peter M HechtCEOSell200,000$15.62$3,124,000.00View SEC Filing  
3/12/2015Joseph C Cook JrDirectorSell5,883$15.54$91,421.82View SEC Filing  
3/10/2015Bryan E RobertsDirectorSell95,998$15.20$1,459,169.60View SEC Filing  
3/3/2015Peter M HechtCEOSell63,442$15.75$999,211.50View SEC Filing  
2/20/2015Joseph C Cook JrDirectorSell35,500$15.60$553,800.00View SEC Filing  
12/15/2014Bryan E RobertsDirectorSell19,792$15.20$300,838.40View SEC Filing  
6/12/2014Bryan E RobertsDirectorSell200,000$14.24$2,848,000.00View SEC Filing  
5/29/2014Michael J HigginsCOOSell50,000$14.56$728,000.00View SEC Filing  
5/22/2014Mark CurrieInsiderSell25,000$13.93$348,250.00View SEC Filing  
4/24/2014Mark CurrieInsiderSell25,000$11.67$291,750.00View SEC Filing  
1/23/2014Mark CurrieInsiderSell20,000$14.38$287,600.00View SEC Filing  
1/14/2014Bryan RobertsDirectorSell21,200$12.57$266,484.00View SEC Filing  
1/13/2014Bryan RobertsDirectorSell823,350$12.71$10,464,778.50View SEC Filing  
1/6/2014Bryan RobertsDirectorSell55,450$12.01$665,954.50View SEC Filing  
11/7/2013Terrance McguireDirectorSell2,083$9.11$18,976.13View SEC Filing  
6/17/2013Michael J HigginsCOOSell150,000$11.74$1,761,000.00View SEC Filing  
3/11/2013Thomas A MccourtInsiderSell40,000$17.00$680,000.00View SEC Filing  
11/5/2012Peter M HechtCEOBuy50,000$11.65$582,500.00View SEC Filing  
10/8/2012Fmr LlcInsiderSell19,305$13.02$251,351.10View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
News IconAnalytical Guide for Six Flags Entertainment Corporation (SIX), Ironwood Pharmaceuticals, Inc. (IRWD) Stakeholders - The USA Commerce (NASDAQ:IRWD) - February 15 at 9:08 PM
News IconNumbers in Focus for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Midway Monitor (NASDAQ:IRWD) - February 15 at 12:24 AM
News IconNew Character Images Released For Universal Survival Arc — Dragon Ball Super (NASDAQ:IRWD) - February 14 at 12:01 AM
News IconThe Ironwood Pharmaceuticals Inc. (IRWD) Shares Bought by Virtus ETF Advisers LLC (NASDAQ:IRWD) - February 14 at 12:01 AM
News IconOrbiMed Advisors is Buying Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Shares - Small Cap Exclusive (press release) (NASDAQ:IRWD) - February 13 at 7:00 PM
News IconForward Earnings Estimate of Ironwood Pharmaceuticals, Inc.(IRWD) - Highland Mirror (NASDAQ:IRWD) - February 12 at 4:04 AM
News IconAnalyst's Predictions on Zayo Group Holdings, Inc. (ZAYO), Ironwood Pharmaceuticals, Inc. (IRWD) - StockNewsJournal (NASDAQ:IRWD) - February 8 at 6:43 PM logoIronwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2016 Investor Update Call (NASDAQ:IRWD) - February 7 at 7:18 PM
News IconQEP Resources, Inc. (QEP), Ironwood Pharmaceuticals, Inc. (IRWD ... - The USA Commerce (NASDAQ:IRWD) - February 3 at 6:32 PM
News IconIronwood Pharmaceuticals Inc (NASDAQ:IRWD): From Top to Bottom - StockNewsJournal (NASDAQ:IRWD) - February 3 at 6:32 PM logo3 Trending Stocks: Ascena Retail Group, Inc. (ASNA), Ironwood ... - iStreetWire (NASDAQ:IRWD) - February 2 at 11:42 PM logo3:46 am Ironwood Pharma and Astellas (ALPMY (NASDAQ:IRWD) - January 30 at 10:38 AM logoIronwood/Astellas Report Positive Phase III Data on Linzess (NASDAQ:IRWD) - January 30 at 10:38 AM logoPremarket Biotech Movers: Ironwood Pharmaceuticals, Rigel Pharmaceuticals, FibroGen (NASDAQ:IRWD) - January 30 at 10:38 AM logoAstellas And Ironwood Report Positive Results From Phase III Linaclotide Trial (NASDAQ:IRWD) - January 29 at 11:17 PM logoIronwood Pharmaceuticals : Astellas And Ironwood Report Positive Results From Phase III Linaclotide Trial (NASDAQ:IRWD) - January 29 at 11:17 PM logoSynergy Pharmaceuticals Inc (SGYP): Canaccord’s Take on Linzess Approval (NASDAQ:IRWD) - January 27 at 5:48 AM
News IconDo Analysts See Any Upside to Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares? (NASDAQ:IRWD) - January 27 at 12:45 AM logoIronwood Pharmaceuticals (IRWD), Allergan (AGN) Gains FDA Approval for 72 mcg Dose of LINZESS (NASDAQ:IRWD) - January 27 at 12:45 AM
News IconIronwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Insider Ownership stands at 0.2 (NASDAQ:IRWD) - January 27 at 12:45 AM logoIronwood Pharmaceuticals, Inc. (NSDQ:IRWD) Has A Near Term Catalyst To Watch - Market Exclusive (NASDAQ:IRWD) - January 26 at 7:42 PM
News IconEquity Insight: Indicator Review for Ironwood Pharmaceuticals Inc. (IRWD) - Springdale Times (NASDAQ:IRWD) - January 26 at 7:42 PM logoU.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS® (linaclotide) for Adults with Chronic Idiopathic Constipation (NASDAQ:IRWD) - January 26 at 7:42 PM logoCanaccord Positive on Synergy Pharmaceuticals Inc’s; Skeptical on Competitor’s Drug Ahead of FDA Approval (NASDAQ:IRWD) - January 26 at 12:26 AM logoStocks Trend Analysis: Stillwater Mining Company (SWC), Ironwood ... - iStreetWire (NASDAQ:IRWD) - January 25 at 7:24 PM logoIronwood Pharmaceuticals, Inc. (IRWD) Has A Near Term Catalyst ... - Insider Monkey (blog) (NASDAQ:IRWD) - January 24 at 6:43 PM
News IconIronwood Pharmaceuticals, Inc. (IRWD) Has A Near Term Catalyst To Watch (NASDAQ:IRWD) - January 24 at 1:13 PM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Wall Street Beacon (NASDAQ:IRWD) - January 21 at 5:47 PM logoFDA OKs Synergy Pharmaceuticals Constipation Drug (NASDAQ:IRWD) - January 20 at 4:07 PM
News IconIronwood Pharmaceuticals Inc IRWD Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IRWD) - January 18 at 6:31 PM
News IconAnalysts Take: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Projected Earnings & Price Targets - Aiken Advocate (NASDAQ:IRWD) - January 17 at 6:08 PM logoETFs with exposure to Ironwood Pharmaceuticals, Inc. : January 17, 2017 (NASDAQ:IRWD) - January 17 at 1:02 PM
News IconLooking at the Tea Leaves for Ironwood Pharmaceuticals, Inc. (IRWD) - The USA Commerce (NASDAQ:IRWD) - January 16 at 5:57 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : January 16, 2017 (NASDAQ:IRWD) - January 16 at 8:52 AM
News IconWill The Needle Move For Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:IRWD) - January 13 at 7:13 PM logoIronwood Pharma (IRWD) to Detail Strong Execution Strategy at JPMorgan Conference - (NASDAQ:IRWD) - January 10 at 6:51 PM logoIRONWOOD PHARMACEUTICALS,INC. (NASDAQ:IRWD) Files An 8-K Termination of a Material Definitive Agreement (NASDAQ:IRWD) - January 9 at 6:43 PM logo4:37 am Ironwood Pharma provides business update; expect >25% CAGR for revenue between 2016 and 2020 (NASDAQ:IRWD) - January 9 at 6:43 PM logoIRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:IRWD) - January 9 at 6:43 PM logoIronwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech (NASDAQ:IRWD) - January 8 at 10:46 PM logoPost Earnings Coverage as Patheon's Q4 Revenue Beat Market Estimates (NASDAQ:IRWD) - January 6 at 6:38 PM logoIronwood Pharma (IRWD) Says FDA Accepts DUZALLO NDA - (NASDAQ:IRWD) - January 5 at 7:19 PM logoIronwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : January 5, 2017 (NASDAQ:IRWD) - January 5 at 7:19 PM logoIRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement (NASDAQ:IRWD) - January 5 at 7:19 PM
News IconIronwood Announces New Drug Application For DUZALLO (Fixed-Dose Combination Of Lesinurad And Allopurinol) Has Been Accepted For FDA Review (NASDAQ:IRWD) - January 4 at 6:52 PM logoIronwood Pharmaceuticals (IRWD) Gains on NDA (NASDAQ:IRWD) - January 4 at 6:52 PM logoIronwood Pharma (IRWD) Says FDA Accepts DUZALLO NDA (NASDAQ:IRWD) - January 4 at 6:52 PM logoIronwood Announces New Drug Application for DUZALLO™ (Fixed-Dose Combination of Lesinurad and Allopurinol) Has Been Accepted for FDA Review (NASDAQ:IRWD) - January 4 at 6:52 PM logoIronwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : January 4, 2017 (NASDAQ:IRWD) - January 4 at 6:52 PM logoIRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and (NASDAQ:IRWD) - January 4 at 6:52 PM


What is Ironwood Pharmaceuticals' stock symbol?

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?

12 analysts have issued 12-month price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $12.00 to $21.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $16.10 in the next year.

When will Ironwood Pharmaceuticals announce their earnings?

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (13.45%), Janus Capital Management LLC (8.50%), Orbimed Advisors LLC (4.95%), State Street Corp (2.59%), EcoR1 Capital LLC (1.95%) and Rubric Capital Management LP (0.87%). Company insiders that own Ironwood Pharmaceuticals stock include Bryan E Roberts, Edward P Owens, Gina Consylman, Halley E Gilbert, Joseph C Cook Jr, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas Graney.

Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Janus Capital Management LLC, Oxford Asset Management, EcoR1 Capital LLC, Guggenheim Capital LLC and Tudor Investment Corp Et Al. Company insiders that have sold Ironwood Pharmaceuticals stock in the last year include Gina Consylman, Halley E Gilbert, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas Graney.

Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?

Ironwood Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Rubric Capital Management LP, State Street Corp, Marshall Wace LLP, FMR LLC, A.R.T. Advisors LLC, Two Sigma Investments LP, Century Capital Management LLC and Sullivan Bruyette Speros & Blaney LLC.

How do I buy Ironwood Pharmaceuticals stock?

Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ironwood Pharmaceuticals stock cost?

One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $17.12.

Ironwood Pharmaceuticals (NASDAQ:IRWD) Chart for Wednesday, February, 22, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Earnings History Chart

Earnings by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Dividend History Chart

Dividend Payments by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Last Updated on 2/22/2017 by Staff